ONCAlert | 2017 San Antonio Breast Cancer Symposium

Radioimmunotherapy as Treatment for AML

Joseph Jurcic, MD
Published Online:9:16 AM, Fri June 20, 2014
Joseph Jurcic, MD, head, Hematologic Malignancies, Columbia University Medical Center, discusses using radioimmunotherapy as a treatment option for patients with AML.

Clinical Pearls
  • Only 40% of patients with AML under the age of 60 are cured while only 10% of patients over the age of 60 are cured. The median survival is approximately 6 months.
  • Radioimmunotherapy is one way that physicians can help develop more effective therapies while reducing toxicity.
  • Initial studies used a beta-emitter but now physicians use alpha particles in therapy.
  • By using alpha particles, physicians are able to target the tumor cell and do less damage to the surrounding normal tissue.

<<< More from "Immunotherapy News from ASCO"
 

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.